1. Pang Y, Liu Z, Han H, Wang B, Li W, Mao C, et al. Peptide SMIM30 promotes HCC development by inducing SRC/YES1 membrane anchoring and MAPK pathway activation. J Hepatol. 2020 Nov;73(5):1155-69. PubMed PMID: 32461121.
2. Zheng Y, Chen Z, Han Y, Han L, Zou X, Zhou B, et al. Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment. Nature communications. 2020 Dec 8;11(1):6268. PubMed PMID: 33293583. Pubmed Central PMCID: 7722722.
3. Wang W, Zou W. Amino Acids and Their Transporters in T Cell Immunity and Cancer Therapy. Molecular cell. 2020;80 (3):384-95.
4. Wu J, Cai J. Dilemma and Challenge of Immunotherapy for Pancreatic Cancer. Dig Dis Sci. 2021;66(2):359-68.
5. Greer RL, Dong X, Moraes AC, Zielke RA, Fernandes GR, Peremyslova E, et al. Akkermansia muciniphila mediates negative effects of IFNgamma on glucose metabolism. Nature communications. 2016 Nov 14;7:13329. PubMed PMID: 27841267. Pubmed Central PMCID: 5114536.
6. Wu R, Chen F, Wang N, Tang D, Kang R. ACOD1 in immunometabolism and disease. Cellular & molecular immunology. 2020 Aug;17(8):822-33. PubMed PMID: 32601305. Pubmed Central PMCID: 7395145.
7. Mouton AJ, Li X, Hall ME, Hall JE. Obesity, Hypertension, and Cardiac Dysfunction: Novel Roles of Immunometabolism in Macrophage Activation and Inflammation. Circulation research. 2020 Mar 13;126(6):789-806. PubMed PMID: 32163341. Pubmed Central PMCID: 7255054.
8. Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, et al. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Cell reports. 2019 Jul 30;28(5):1370-84 e5. PubMed PMID: 31365877. Pubmed Central PMCID: 7546539.
9. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harbor perspectives in biology. 2010 Jan;2(1):a001008. PubMed PMID: 20182602. Pubmed Central PMCID: 2827900.
10. Mogi A, Kuwano H. TP53 mutations in nonsmall cell lung cancer. Journal of biomedicine & biotechnology. 2011;2011:583929. PubMed PMID: 21331359. Pubmed Central PMCID: 3035360.
11. Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. European journal of cancer. 2017 Sep;83:258-65. PubMed PMID: 28756138.
12. Silwal-Pandit L, Langerod A, Borresen-Dale AL. TP53 Mutations in Breast and Ovarian Cancer. Cold Spring Harbor perspectives in medicine. 2017 Jan 3;7(1). PubMed PMID: 27815305. Pubmed Central PMCID: 5204332.
13. Yang C, Huang X, Li Y, Chen J, Lv Y, Dai S. Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology. Briefings in bioinformatics. 2021 May 20;22(3). PubMed PMID: 32789496.
14. Meng F, Wu L, Dong L, Mitchell AV, James Block C, Liu J, et al. EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming. Nature communications. 2019 Nov 6;10(1):5033. PubMed PMID: 31695034. Pubmed Central PMCID: 6834558.
15. Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nature medicine. 2018 Oct;24(10):1550-8. PubMed PMID: 30127393. Pubmed Central PMCID: 6487502.
16. Pinero F, Dirchwolf M, Pessoa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells. 2020 Jun 1;9(6). PubMed PMID: 32492896. Pubmed Central PMCID: 7349517.
17. Golonka RM, Vijay-Kumar M. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome. Advances in cancer research. 2021;149:171-255. PubMed PMID: 33579424.
18. Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, et al. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. JAMA oncology. 2020 Dec 1;6(12):e204930. PubMed PMID: 33090186. Pubmed Central PMCID: 7582230.
19. Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nature reviews Clinical oncology. 2018 Oct;15(10):599-616. PubMed PMID: 30061739.
20. Juhling F, Hamdane N, Crouchet E, Li S, El Saghire H, Mukherji A, et al. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. Gut. 2021 Jan;70(1):157-69. PubMed PMID: 32217639. Pubmed Central PMCID: 7116473.
21. Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell death and differentiation. 2019 Jan;26(2):199-212. PubMed PMID: 30538286. Pubmed Central PMCID: 6329812.
22. Li L, Li M, Wang X. Cancer type-dependent correlations between TP53 mutations and antitumor immunity. DNA repair. 2020 Apr;88:102785. PubMed PMID: 32007736.
23. Agupitan AD, Neeson P, Williams S, Howitt J, Haupt S, Haupt Y. P53: A Guardian of Immunity Becomes Its Saboteur through Mutation. Int J Mol Sci. 2020 May 13;21(10). PubMed PMID: 32414156. Pubmed Central PMCID: 7278985.
24. Jelski W, Szmitkowski M. Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) in the cancer diseases. Clinica chimica acta; international journal of clinical chemistry. 2008 Sep;395(1-2):1-5. PubMed PMID: 18505683.
25. Lercher A, Baazim H, Bergthaler A. Systemic Immunometabolism: Challenges and Opportunities. Immunity. 2020;53(3):496-509.
26. Pineiro Fernandez J, Luddy KA, Harmon C, O'Farrelly C. Hepatic Tumor Microenvironments and Effects on NK Cell Phenotype and Function. Int J Mol Sci. 2019 Aug 24;20(17). PubMed PMID: 31450598. Pubmed Central PMCID: 6747260.
27. Garnelo M, Tan A, Her Z, Yeong J, Lim CJ, Chen J, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut. 2017 Feb;66(2):342-51. PubMed PMID: 26669617. Pubmed Central PMCID: 5284473.
28. Giannone G, Ghisoni E, Genta S, Scotto G, Tuninetti V, Turinetto M, et al. Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy. Int J Mol Sci. 2020 Jun 21;21(12). PubMed PMID: 32575899. Pubmed Central PMCID: 7352562.